February 28, 2022 5:13pm
The sector evolved in volatile trading; be aware the algorithms are lurking to adjust percentage (%) upsides for profit as March begins tomorrow
Pre-open indications: 5 Hits and 3 Miss
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts at the end of February
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -179.20 points (-0.53%); the S&P closed DOWN -10.87 points (-0.25%) while the Nasdaq closed UP +56.78 points (+0.41%)
Henry’omics:
Monday’s moves capped off a rough February for stocks, with the major averages all posting sharp monthly losses.
Indexes slid, cut early losses with the Nasdaq going positive as the close came nearer on Monday after a new batch of sanctions from the U.S. and its allies.
RegMed Investors’ (RMi) pre-open: “Again, I ask what’s sustainable in this warring geo-political turmoil? … https://www.regmedinvestors.com/articles/12318
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Monday opened negative at 6 up/26 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 20/13, 1 flat and 1 acquired, ending with a positive close of 18/16 and 1 acquired;
- Friday opened negative at 9 up/21 downs, 4 flats and 1 acquired, flipped positive at the mid-day at 17/15, 2 flats and 1 acquired, ending with a positive close of 23/8, 3 flats and 1 acquired;
Pre-open Indications: 5 Hits <Biostage (OTCQB: BSTG -$0.00), Athersys (ATHX -$0.03), BioLife Solutions (BLFS -$0.29), ReNeuron (RENE.L -$2.00), Sage Therapeutics (SAGE -$0.28)> 3 Miss < CRISPR Therapeutics (CRSP +0.95), Vericel (VCEL +$1.75), Editas Medicine (EDIT +$0.22),
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … added (BLFS), (MDXG) and (FATE) today
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Monday with 687 shares traded +$0.37 just before the close after Friday closed flat with 70 shares traded and Thursday with the shares dumping -$0.67 on 1,259 shares traded
Key Metrics:
- Monday - Sector volume was LOW with 3 of the 18-upside having higher than the 3-month average volume with LOW volume of 3 of 16-downside having higher than the 3-month average volume;
- Friday - Sector volume was LOW with 6 of the 23-upside having higher than the 3-month average volume with LOW volume of 0 of 8-downside having higher than the 3-month average volume
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday the IBB closed down -0.17% and XBI closed up +0.13%
- Friday the IBB closed up +1.36% and XBI closed up +0.90%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +2.49 points or +9.13% at 30.11
- Friday was down -2.73 points or -9% at 27.59
Jumping with share pricing momentum (10 of 18):
- Alnylam Pharmaceuticals (ALNY +$2.85),
- Intellia Therapeutics (NTLA +$2.49 after Friday’s +$8.90),
- Vericel (VCEL +$1.99 after Friday’s +$0.34),
- CRISPR Therapeutics (CRSP +$1.64 after Friday’s +$2.57),
- Ionis Pharmaceuticals (IONS +$1.60 after Friday’s -$0.71),
- Homology Medicine (FIXX +$0.73),
- Regenxbio (RGNX +$0.38),
- Biostage (BSTG +$0.37 after Friday’s $0.00),
- Global Blood Therapeutics (GBT +$0.36 after Friday’s -$0.36),
Hammered in today’s market (10 of 16):
- ReNeuron (RENE.L -$2.00 after Friday’s +$1.00),
- Fate Therapeutics (FATE -$0.38 after Friday’s +$0.98),
- BioLife Solutions (BLFS -$0.29),
- Sage Therapeutics (SAGE -$0.28 after Friday’s +$1.94),
- Chinook Therapeutics (KDNY -$0.22 after Friday’s -$0.31),
- bluebird bio (BLUE -$0.13),
- Ultragenyx (RARE -$0.13 after Friday’s -$0.37),
- Mesoblast (MESO -$0.08),
- AxoGen (AXGN -$0.05 after Friday’s +$0.45),
- Sangamo Therapeutics (SGMO -$0.05 after Friday’s +$0.19),
Closing:
1 - Stemline Therapeutics (STML) – acquired
February, Q1/2022:
Monday (2/28) closed positive with 18 incliners, 16 decliners and 1 acquired
Friday closed positive with 23 incliners, 8 decliners, 3 flats and 1 acquired
Thursday closed positive with 27 incliner, 7 decliners and 1 acquired
Wednesday closed negative with 8 incliner, 26 decliners and 1 acquired
Tuesday closed negative with 7 incliners, 25 decliners, 2 flats and 1 acquired
Monday (2/21) was a holiday, President’s Day
Friday closed negative with 3 incliners, 28 decliners, 3 flats and 1 acquired
Thursday closed negative with 4 incliner, 29 decliners, 1 flat and 1 acquired
Wednesday closed negative with 8 incliner, 22 decliners, 4 flats and 1 acquired
Tuesday closed positive with 31 incliners, 1 decliner, 2 flat and 1 acquired
Monday (2/14) closed negative with 4 incliners, 28 decliners, 2 flats and 1 acquired
Friday closed negative with 3 incliner, 32 decliners and 1 acquired
Thursday closed negative with 5 incliner, 28 decliners, 1 flat and 1 acquired
Wednesday closed positive with 31 incliner, 3 decliners and 1 acquired
Tuesday closed negative with 14 incliners, 19 decliners, 1 flat and 1 acquired
Monday (2/7) closed positive with 29 incliners, 4 decliners, 1 flat and 1 acquired
Friday closed positive with 30 incliners, 4 decliners and 1 acquired
Thursday closed negative with 5 incliners, 27 decliners, 2 flats and 1 acquired
Wednesday closed negative with 1 incliner, 33 decliners and 1 acquired
Tuesday (2/1) closed positive with 26 incliners, 7 decliners, 1 flat and 1 acquired
The BOTTOM LINE: I thought that Monday’s war footing escalation would dominate a downside and it never happen to our sector – maybe I should be a better believer?
Although, it’s better to be prepared and be surprised and happy for any share pricing appreciation even as indexes decline.
We all remember the adage, “It takes two to make a market"; that’s sellers and buyers.
I am always anticipating the risks – as my careers focus has been “warning analysis”.
The cell and gene therapy sector extend few gains but our universe is still positive.
Investors are watching earnings reports this today; as many of those reporting TODAY are showing a positive share pricing.
Q4 and end-of-year earnings are gaming than even I thought.
Earnings’ reporting:
· MiMedx MDXG) Monday, 2/28
· Regenxbio (RGNX), Tuesday, 3/1
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
